This article reviews the targeting of CGRP, a biomarker of migraine, as a treatment for the disorder and efforts to develop mechanism-based therapies.
Peter Goadsby discusses his extensive research in headache disorders, including the pathophysiology of headaches, rare forms and research needs within the field.
The American Academy of Neurology (AAN) have released new guidelines for the treatment of spasticity, cervical dystonia, blepharospasm and migraine with botulinum toxin at their annual meeting in Vancouver (15 – 21st April, Vancouver, BC, Canada).
A new study suggests that persistent neurological problems in Ebola survivors are common.
We will describe the pharmacokinetic profile, clinical efficacy and safety data of the sumatriptan iontophoretic transdermal system (Zecuity®, NuPathe Inc.,…
This editorial discusses the use of botulinum neurotoxin A in preventing headaches in adult patients with chronic migraine.